Table 5.
Sensitivity and 95% CIs of diagnostic techniques and resistance detection in the groups stratified by the BI.
| Bacilloscopic Index |
|||||
|---|---|---|---|---|---|
| Test | ≥ 2 (n = 21) | < 2 (n = 35) | 0+(Negative BI) | Total | p-value |
| PCR RLEP | |||||
| PureLink Kit | 19 (90.48%) (71.09-97.35) |
15 (42.86%) (27.98-59.14) |
9 (40.90%) (23.26-61.27) |
34 (60.71%) (47.63-72.42) |
<0.001 |
| Nucleospin TXS | 19 (90.48%) (71.09-97.35) |
12 (34.29%) (20.83-50.85) |
7 (31.81%) (16.36-52.68) |
31 (55.36%) (42.41-67.61) |
<0.001 |
| Complementary sensitivity* | |||||
| folP1 | 19 (90.48%) (71.09-97.35) |
8 (22.86%) (12.07-39.02) |
5 (22.73%) (10.12-43.44) |
27 (48.21%) (35.67-60.99) |
<0.001 |
| rpoB | 19 (90.48%) (71.09-97.35) |
7 (20.00%) (10.04-35.89) |
3 (13.64%) (4.749-33.34) |
26 (46.43%) (34.02-59.30) |
<0.001 |
| gyrA | 16 (76.19%) (54.91-89.37) |
5 (14.28%) (6.26-29.38) |
2 (9.09%) (2.529-27.82) |
21 (37.50%) (26.01-50.59) |
<0.001 |
⁎
For sensitivity calculation, we considered a result positive if either of the extraction kits resulted in the amplification of the target genetic sequence.
PureLink, PureLink Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific, Waltham, Massachusetts, USA); Nucleospin TXS, NucleoSpin Tissue XS (Macherey-Nagel, GmbH & Co. KG, Düren, Germany); folP1, dapsone resistance-associated target; rpoB, rifampicin resistance-associated target; gyrA, quinolone resistance-associated target.